Original Research

Published in:
Volume 7 / Year 2018 / Issue 2

Patient-reported outcome measures in phase III trials of LY2963016 insulin glargine and reference insulin glargine products: ELEMENT 1 and ELEMENT 2

Author(s): , , , , , ,
Page: 56-62

Background: This analysis evaluates the patient-reported outcomes (PROs) in two randomized studies of biosimilar LY2963016 insulin glargine (LY IGlar) and Lantus® insulin glargine (IGlar), when used in combination with mealtime… Read More »

Go Back Print